EUCTR2018-002688-24-FR进行中（未招募）1 期
Phase I-II study of nivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade glioma - NIVOGLIO
Gustave Roussy0 个研究点目标入组 40 人开始时间: 2019年2月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines
- •2.Age at inclusion: ? 3 to <18 years of age
- •3.Patients should be able and willing to comply with study visits and procedures as per protocol.
- •4.Patients must be affiliated to a social security system or beneficiary of the same according to local requirements
- •5.Sexually actice females of childbearing potential must have a negative serum pregnancy test within 24 hours prior to initiation of treatment. Sexually active women of childbearing potential must agree to use acceptable and appropriate contraception during the study and for at least 5 months after the last study treatment administration. Sexually active males patients (and their female partner) must agree to use condom during the study and for at least 7 months after the last study treatment administration. Acceptable contraception is listed in Appendix 7.
- •6.Newly diagnosed non-brainstem WHO grade III and IV HGG and neuroglial tumors; gliomatosis cerebri or diffuse glioma, metastatic malignant glial tumors, multifocal gliomas and bithalamic gliomas are eligible for the study. Diffuse midline gliomas with H3K27M mutation are not eligible. Anaplastic ganglioglioma and anaplastic pleïomorphic astrocytoma will be eligible.
- •7.Local histological diagnosis has been confirmed centrally by a designated reference pathologist.
- •8.Able to commence trial treatment within 6 weeks following the last major surgery.
- •9.Adequate Bone Marrow Function : Hemoglobin ? 10 g/dL (transfusion independent), Neutrophil count ? 1.0 ? 109/L. Platelet count ? 100 ? 109/L (transfusion independent)
- •10.Absence of Coagulation Disorder
- •11.Adequate Liver Function : AST ? 2.5x institutional ULN for age, ALT ? 2.5x institutional ULN for age, Total Bilirubin ? 1.5x institutional ULN for age
- •12.Adequate Renal Function : Serum creatinine must be ? 1.5x ULN for age, absence of clinically significant proteinuria as defined by a screening early morning urine (first sample) dipstick urinalysis of ?2
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any disease or condition that contraindicates the use of the study medication/treatment (for TMZ, see the approved product labelling) or places the patient at an unacceptable risk of experiencing treatment related complications.
- •2.Patients should not be on high-dose steroids (ie > 1mg/kg) before study entry; doses should be stable for at least two weeks or decreasing.
- •3.Low probability of protocol compliance.
- •4.Radiological evidence of surgically related intracranial bleeding (excluding asymptomatic, resolving hemorrhagic changes associated with recent surgery and the presence of punctuate hemorrhage in the tumor).
- •5.Subjects with concommitant second malignanices are excluded unless a complete remission is achieved as it is empirically determined based on the malignancy and treatment provided prior to study entry and no additional therapy is required or anticipated to be required during the study period.
- •6.Previous cranial irradiation.
- •7.Any known auto-immune disease, previous or ongoing.
- •8.Known chronic inflammatory digestive disease, previous or ongoing.
- •9.Chronic asthma receiving corticotherapy, even only with inhalation.
- •10.Vaccinated with live attenuated vaccines within 4 weeks of the first dose of study drug
- •11.Pregnant or breastfeeding women
- •12.Known hypersensitivity to any component of the products (study drug or ingredients)
- •13.Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
- •14.Patients who are currently receiving another investigational drug or anticancer agent
- •15.Patient who have an uncontrolled infection
- •16.Patient with known human immunodeficiency virus (HIV) / AIDS infection or acute / chronic Hepatitis B or C
研究者
相似试验
进行中（未招募）
1 期
Treatment of advanced lung cancerPatients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003334-25-DEniversity of Cologne90
招募中
1 期
Phase I trial of a treatment of nivolumab combined with stereotactic body radiotherapy for patients with multiple metastatic non-small cell lung cancer.non-small cell lung cancer with two or more lesions including at least lung or plueraJPRN-UMIN000023645Department of Radiology, University of Yamanashi12
进行中（未招募）
1 期
A randomised phase II trial comparing two different ways of combining nivolumab and ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.Previously untreated metastatic clear cell renal cell carcinoma.MedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001476-33-GBniversity of Leeds189
进行中（未招募）
1 期
Combination study between nivolumab and metformin in advanced kidney cancer.EUCTR2019-004916-76-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE21
进行中（未招募）
1 期
A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapyMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002986-36-ITFONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI184